Tablets with 50000UI cholecalciferol (vitamin D3) will be administered, weekly, for six months.

The patients selected to the placebo group will receive inert content tablets without therapeutic effect, weekly, for six months.

Crohn Disease

Vitamin D Deficiency

Fatigue

Sarcopenia

Muscle Weakness

Disorder of Bone Density and Structure, Unspecified

investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D

Vitamin D

compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D

Placebo

Universidade Federal de Juiz de Fora

Effects of Supplementation of Vitamin D in Patients With Crohn`s Disease

The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial

MBD assessed by DXA, expressed in gr/cm²

Improvement in the distance achieved in the SWT expressed in meters (m)

Body mass will be assessed by DXA and will be expressed in kg

Fatigue will be measured by the Chalder Fatigue Questionnaire (CFQ). The CFQ is analyzed by 2 domains physical and mental (cutoff: patient's total score higher than 2)

Lorena Nagme de Oliveira Pinto

lecturer

Federal University of Juiz de Fora

Fundação de Amparo à Pesquisa do estado de Minas Gerais

A double-blind, randomized, placebo-controlled study will be performed. After the evaluation of serum vitamin D levels, patients with vitamin D below 30ng/mL will be randomized into two groups. One group will receive supplementation with cholecalciferol (vitamin D3) tablets and the other group will receive placebo. Those will be provided at no cost to the patients. The dosage of 1.500-2.000 IU (International Units) vitamin D/day is recommended in order to meet the need of vitamin D above 30ng/mL in adults. However, a dose at least 2 to 3 times higher is recommended for CD patients due to malabsorption, significant loss of adipose tissue and use of glucocorticoids. Thus, the dose of 50,000IU/week will be administered in a single dose. The patients drawn to the placebo group will receive inert content tablets without therapeutic effect. After the study completion, these control patients will receive complete treatment for hypovitaminosis D.

Only the pharmacist responsible for confection of the tablets will know who will receive vitamin d or placebo, according to a list of randimization generated in the computer by the statistician. The list will be kept with the pharmacist throughout the intervention.

Sedron (alendronate) 70 mg taken orally once a week for 12 months

Primary Hyperparathyroidism

Sedron (alendronate)

Parathyroidectomy

Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University

OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism

Osteoprotegerin/sRANKL Ratio and Bone Mineral Density in Patients With Primary Hyperparathyroidism Treated With Parathyroidectomy or Alendronate

Jadwiga Szymczak

assistant professor

Wroclaw Medical University

Ministry of Science and Higher Education, Poland

Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.

Healthy Control

Crohn's Disease

Total

Sex: Female, Male

Region of Enrollment

Intestinal Absorption of Calcium

Fractional absorption of calcium (see citation for complete details)

Fractional Absorption of Calcium

Overall Study

Vin Tangpricha, M.D., Ph.D.

Rheumatoid Arthritis

0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose

hypercalciuria/akuutti patologinen solukuolema

Effects of Supplementation of Vitamin D in Patients With Crohn`s Disease

OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism

Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption

Täydellisin lääketieteellinen tietokanta tieteen tukemana